3rd Annual Gene Therapy for Rare Disorders EuropePublished: September 12, 2019
Hanson Wade brings together leading experts in the field for the 3rd Annual Gene Therapy for Rare Disorders Europe conference, from 15th-17th October 2019 in London, UK.
The meeting is solely focused on discussing the latest clinical, manufacturing, regulatory and commercialization challenges that need to be overcome to deliver the next generation of gene therapies to market.
It will bring together leading experts from big pharma, innovative biotechs, academics and key service provider companies in the gene therapy field to discuss the critical factors involved in driving commercial success for gene therapies in the complex European landscape.
The meeting starts with two workshops that will use case-studies to discuss how best to utilize incentives to develop gene therapies in the rare disease space and the importance of gearing up for commercialization from early in product development.
Day 1 of the conference will focus on topics related to the current industry landscape for gene therapies in the rare disease space, ways to enhance clinical development, how to establish robust, scalable and cost-effective manufacturing processes and incorporating the patient perspective in clinical development.
Day 2 will address topics related to the European regulatory environment, articulating the value of gene therapies to overcome market access challenges, developing effective characterization and analytical tools, and exploring the potential of lentiviral as well as AAV vectors.
Detailed information on the conference agenda and registration process is available here